Patients 18 years or older with biopsy (histopathologically) confirmed cutaneous T-cell
lymphoma (limited to mycosis fungoides (MF)) who have had prior therapy with at least one
and no more than 3 systemic treatments.
Patients with visceral involvement, serious infection or illness including human
immunodeficiency virus infection, or a Karnofsky Performance Status (KPS) excluded.